Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.56 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | CTSV | O60911 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CTSC | P53634 | 1/20 | 0.42 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16732580 | 0.87 | KLK7 (0.55) | KLK7STSGPR119MEN1KMT2A | |
| SCHEMBL7511892 | 0.87 | KLK7 (0.55) | KLK7STSGPR119MEN1KMT2A | |
| SCHEMBL21996511 | 0.87 | KLK7 (0.57) | KLK7STSGPR119MEN1KMT2A | |
| SCHEMBL7698816 | 0.87 | KLK7 (0.55) | KLK7STSGPR119MEN1KMT2A | |
| SCHEMBL1150828 | 0.87 | KLK7 (0.55) | KLK7STSGPR119MEN1KMT2A | |
| SCHEMBL10035703 | 0.85 | KLK7 (0.53) | KLK7STSGPR119MEN1KMT2A | |
| SCHEMBL16943520 | 0.84 | KLK7 (0.57) | KLK7STSGPR119MEN1KMT2A | |
| SCHEMBL21996541 | 0.84 | KLK7 (0.57) | KLK7STSGPR119MEN1KMT2A | |
| SCHEMBL16943519 | 0.84 | KLK7 (0.57) | KLK7STSGPR119MEN1KMT2A | |
| SCHEMBL13495419 | 0.83 | KLK7 (0.54) | KLK7STSGPR119MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1950198-B1 | PROCESS FOR PRODUCTION OF BENZYLOXYPYRROLIDINE DERIVATIVE, AND PROCESS FOR PRODUCTION OF HYDROCHLORIDE SALT POWDER OF OPTICALLY ACTIVE BENZYLOXYPYRROLIDINE DERIVATIVE | TORAY FINECHEMICALS CO LTD (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-7772406-B2 | Process for production of benzyloxypyrrolidine derivative, and process for production of hydrochloride salt powder of optically active benzyloxypyrrolidine derivative | TORAY FINE CHEMICALS CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090093643-A1 | Process for Production of Benzyloxypyrrolidine Derivative, and Process for Production of Hydrochloride Salt Powder of Optically Active Benzyloxypyrrolidine Derivative | TORAY FINE CHEMICALS CO., LTD. (JP) | 2009-04-09 | — | — | US | disclosed |
| EP-1950198-A1 | PROCESS FOR PRODUCTION OF BENZYLOXYPYRROLIDINE DERIVATIVE, AND PROCESS FOR PRODUCTION OF HYDROCHLORIDE SALT POWDER OF OPTICALLY ACTIVE BENZYLOXYPYRROLIDINE DERIVATIVE | Toray Fine Chemicals Co., Ltd. (JP) | 2008-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093643-A1 | Process for Production of Benzyloxypyrrolidine Derivative, and Process for Production of Hydrochloride Salt Powder of Optically Active Benzyloxypyrrolidine Derivative | HPD, PAH, DHPS | KLK7 3999/4885STS 2393/4885GPR119 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.